Protagonist Therapeutics, Inc
PTGX Real Time Price USDRecent trades of PTGX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by PTGX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
PTGX Revenue by Segment or Geography
New patents grants
-
Patent Title: Hepcidin analogues and uses thereof Apr. 08, 2025
-
Patent Title: Conjugated hepcidin mimetics Feb. 25, 2025
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jan. 30, 2024
-
Patent Title: Α4β7 thioether peptide dimer antagonists Dec. 12, 2023
-
Patent Title: Hepcidin analogues and uses thereof Nov. 07, 2023
-
Patent Title: Conjugated hepcidin mimetics Sep. 12, 2023
-
Patent Title: Analogues of hepcidin mimetics with improved in vivo half lives Oct. 18, 2022
-
Patent Title: Α4α7 peptide monomer and dimer antagonists Sep. 07, 2021
-
Patent Title: Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Jun. 22, 2021
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Mar. 09, 2021
-
Patent Title: Opioid agonist peptides and uses thereof Aug. 04, 2020
-
Patent Title: Hepcidin analogues and uses thereof Dec. 10, 2019
-
Patent Title: Hepcidin analogues and uses thereof Oct. 15, 2019
-
Patent Title: Methods for synthesizing α4β7 peptide antagonists Sep. 10, 2019
-
Patent Title: Cyclic monomer and dimer peptides having integrin antagonist activity May. 28, 2019
-
Patent Title: Opioid agonist peptides and uses thereof May. 07, 2019
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Feb. 05, 2019
-
Patent Title: Α4β7 thioether peptide dimer antagonists Aug. 28, 2018
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 31, 2018
-
Patent Title: Hepcidin analogues and uses thereof Jul. 24, 2018
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Jul. 17, 2018
-
Patent Title: Hepcidin analogues and uses thereof Nov. 21, 2017
-
Patent Title: Α4β7 peptide monomer and dimer antagonists Nov. 07, 2017
-
Patent Title: A4b7 integrin thioether peptide antagonists Jul. 25, 2017
-
Patent Title: Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases Apr. 18, 2017
-
Patent Title: Α4β7 peptide dimer antagonists Mar. 01, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to PTGX
Recent picks made for PTGX stock on CNBC
ETFs with the largest estimated holdings in PTGX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $PTGX stock a Buy, Sell, or Hold?
- What is the price target for $PTGX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $PTGX stock?
- Who owns the most shares of $PTGX stock?
- What funds own $PTGX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view PTGX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.